Literature DB >> 24404580

The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.

Qian Zhang, Fang Wei, Hong Yi Wang, Xiaobin Liu, Darshan Roy, Qun-Bin Xiong, Shuguang Jiang, Andrew Medvec, Gwenn Danet-Desnoyers, Christopher Watt, Ewa Tomczak, Michael Kalos, James L Riley, Mariusz A Wasik.   

Abstract

With this study we have demonstrated that in vitro transduction of normal human CD4(+) T lymphocytes with NPM-ALK results in their malignant transformation. The transformed cells become immortalized and display morphology and immunophenotype characteristic of patient-derived anaplastic large-cell lymphomas. These unique features, which are strictly dependent on NPM-ALK activity and expression, include perpetual cell growth, proliferation, and survival; activation of the key signal transduction pathways STAT3 and mTORC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive cytokine IL-10 and cell-surface protein PD-L1/CD274. Implantation of NPM-ALK-transformed CD4(+) T lymphocytes into immunodeficient mice resulted in formation of tumors indistinguishable from patients' anaplastic large-cell lymphomas. Our findings demonstrate that the key aspects of human carcinogenesis closely recapitulating the features of the native tumors can be faithfully reproduced in vitro when an appropriate oncogene is used to transform its natural target cells; this in turn points to the fundamental role in malignant cell transformation of potent oncogenes expressed in the relevant target cells. Such transformed cells should permit study of the early stages of carcinogenesis, and in particular the initial oncogene-host cell interactions. This experimental design could also be useful for studies of the effects of early therapeutic intervention and likely also the mechanisms of malignant progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24404580      PMCID: PMC5745542          DOI: 10.1016/j.ajpath.2013.08.030

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.

Authors:  Qian Zhang; Puthryaveett N Raghunath; Liquan Xue; Miroslaw Majewski; David F Carpentieri; Niels Odum; Stephan Morris; Tomasz Skorski; Mariusz A Wasik
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

2.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells.

Authors:  B Elenbaas; L Spirio; F Koerner; M D Fleming; D B Zimonjic; J L Donaher; N C Popescu; W C Hahn; R A Weinberg
Journal:  Genes Dev       Date:  2001-01-01       Impact factor: 11.361

3.  CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

Authors:  Mangeng Cheng; Matthew R Quail; Diane E Gingrich; Gregory R Ott; Lihui Lu; Weihua Wan; Mark S Albom; Thelma S Angeles; Lisa D Aimone; Flavio Cristofani; Rodolfo Machiorlatti; Cristina Abele; Mark A Ator; Bruce D Dorsey; Giorgio Inghirami; Bruce A Ruggeri
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

4.  Advancing the STATus of MPN pathogenesis.

Authors:  Neil P Shah; Kevin Shannon
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

5.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

Authors:  Roberto Chiarle; Jerald Z Gong; Ilaria Guasparri; Anna Pesci; Jonjing Cai; Jian Liu; William J Simmons; Girish Dhall; Jennifer Howes; Roberto Piva; Giorgio Inghirami
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

6.  Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

Authors:  M Marzec; M Kasprzycka; X Liu; M El-Salem; K Halasa; P N Raghunath; R Bucki; P Wlodarski; M A Wasik
Journal:  Oncogene       Date:  2007-03-12       Impact factor: 9.867

7.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.

Authors:  Alberto Zamo; Roberto Chiarle; Roberto Piva; Jennifer Howes; Yan Fan; Marco Chilosi; David E Levy; Giorgio Inghirami
Journal:  Oncogene       Date:  2002-02-07       Impact factor: 9.867

8.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

9.  Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.

Authors:  Tan A Ince; Andrea L Richardson; George W Bell; Maki Saitoh; Samuel Godar; Antoine E Karnoub; James D Iglehart; Robert A Weinberg
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

10.  Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5).

Authors:  J Fujimoto; M Shiota; T Iwahara; N Seki; H Satoh; S Mori; T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

View more
  13 in total

Review 1.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

Review 2.  Engineering T Cells to Functionally Cure HIV-1 Infection.

Authors:  Rachel S Leibman; James L Riley
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

3.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Authors:  F Abate; M Todaro; J-A van der Krogt; M Boi; I Landra; R Machiorlatti; F Tabbò; K Messana; C Abele; A Barreca; D Novero; M Gaudiano; S Aliberti; F Di Giacomo; T Tousseyn; E Lasorsa; R Crescenzo; L Bessone; E Ficarra; A Acquaviva; A Rinaldi; M Ponzoni; D L Longo; S Aime; M Cheng; B Ruggeri; P P Piccaluga; S Pileri; E Tiacci; B Falini; B Pera-Gresely; L Cerchietti; J Iqbal; W C Chan; L D Shultz; I Kwee; R Piva; I Wlodarska; R Rabadan; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2014-12-23       Impact factor: 11.528

Review 4.  MYC: Master Regulator of Immune Privilege.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Trends Immunol       Date:  2017-02-21       Impact factor: 16.687

5.  Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.

Authors:  Qian Zhang; Hong Y Wang; Anindita Nayak; Selene Nunez-Cruz; Artur Slupianek; Xiaobin Liu; Johnvesly Basappa; Jing-Song Fan; Seble Chekol; Reza Nejati; Agata M Bogusz; Suzanne D Turner; Kunchithapadam Swaminathan; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

6.  Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining.

Authors:  Hind Ghezraoui; Marion Piganeau; Benjamin Renouf; Jean-Baptiste Renaud; Annahita Sallmyr; Brian Ruis; Sehyun Oh; Alan E Tomkinson; Eric A Hendrickson; Carine Giovannangeli; Maria Jasin; Erika Brunet
Journal:  Mol Cell       Date:  2014-09-04       Impact factor: 17.970

7.  ALK-transformed mature T lymphocytes restore early thymus progenitor features.

Authors:  Annabelle Congras; Coralie Hoareau-Aveilla; Nina Caillet; Marie Tosolini; Patrick Villarese; Agata Cieslak; Laura Rodriguez; Vahid Asnafi; Elisabeth Macintyre; Gerda Egger; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

8.  NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation.

Authors:  David L Cookmeyer; Damian Maseda; John K Everett; Jan M Pawlicki; Fang Wei; Hong Kong; Qian Zhang; Hong Y Wang; John W Tobias; David M Walter; Kelly M Zullo; Sarah Javaid; Amanda Watkins; Mariusz A Wasik; Frederic D Bushman; James L Riley
Journal:  Cancer Res       Date:  2021-02-22       Impact factor: 13.312

Review 9.  Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities.

Authors:  Fabrizio Tabbò; Marco Pizzi; Peter W Kyriakides; Bruce Ruggeri; Giorgio Inghirami
Journal:  Oncotarget       Date:  2016-05-03

10.  Challenging perspectives on the cellular origins of lymphoma.

Authors:  Tim I M Malcolm; Daniel J Hodson; Elizabeth A Macintyre; Suzanne D Turner
Journal:  Open Biol       Date:  2016-09       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.